RPC1063
Phase 3Small molecule
Bristol-Myers SquibbRPC1063 is one of 60 small molecule programs targeting Ulcerative Colitis. It is currently in Phase 3.
2
Indications
6
Total Trials
0
Active Trials
59
Competitors
Pipeline
Status by Indication[3][1]
Competition
Competitive Landscape
560 competitors in Multiple Sclerosis
#DrugCompanyPhaseTrials
1Kesimpta
NovartisPreclinical
RPC1063
Bristol-Myers SquibbPhase 3
Avonex
EMD SeronoPreclinical
Campath
GGenzyme, a Sanofi Company
Preclinical
Zinbryta
RochePreclinical
Flomax
SanofiPreclinical
Myfortic
NovartisPreclinical
Novantrone
PfizerPreclinical
Lunesta
Akero TherapeuticsPreclinical
XEOMIN
MMerz Pharmaceuticals GmbH
Preclinical
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Clinical
Trials by Indication[1]
Ulcerative Colitis2 trials
Single Dose1 trial
Moderate to Severe Crohn's Disease1 trial
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for RPC1063. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details
Drug Info
Quick Facts
- Modality
- Small molecule[2]
- Highest Phase
- Phase 3[1]
- Company